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Randomized clinical trials (RCTs) demonstrated the equal efﬁcacy of urinary human chorionic
gonadotropin (uhCG) and recombinant hCG (rhCG) products in in vitro fertilisation (IVF). However,
limitations inherent with RCTs necessitate the reinforcement of RCT results in real-life. We
retrospectively analyzed pregnancies after treatment with rhCG and uhCG products (n = 391,
and 96, resp.). We found that laboratory-veriﬁed pregnancy occurred more frequently in rhCG
patients than in those on uhCG (43% versus 30%, P = 0.02). The association remains signiﬁcant
(P = 0.002) after its adjustment for clinical characteristics. The prevalence of laboratory-veriﬁed
pregnancies was higher with GnRH agonist use (P = 0.012) and BMI under 30kg/m2 (P = 0.053)
while decreased the age (P =0.014) and the number of previous failed attempts (P =0.08). Similar
(but not signiﬁcant) trends were observed with rates of pregnancy ﬁlled the 24th week. These
results reinforce RCTs supporting the notion that rhCG is more efﬁcient as uhCG during IVF.
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nancy
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1. INTRODUCTION
The use of human chorionic gonadotropins (hCGs) to achieve ﬁnal follicular maturation and triggering fol-
licular rupture is well established in women undergoing ovulation induction.
During the spontaneous menstrual cycle, a preovulatory LH surge initiates the ovulation. However,
in order to avoid premature rupture of follicles during in vitro fertilization, the spontaneousLH surge is pre-
vented by the administration of GnRH agonists or antagonists and the ovulation is induced artiﬁcially. For
ovulation induction, exogenous hCG is used due to its pharmacological effects on LH receptor [1].
hCGs in pharmacological preparations were originally derived from urinary samples of pregnant
women. Urinary hCG (uhCG) products may have, however, great biological variability with a signiﬁcant
batch-to-batch variation due to their human origin. Therefore, recombinant technology has been introduced
for the production of recombinant hCG (rhCG) with high-purity and batch-to-batch consistency. Other
advantage of rhCG products over uhCG preparation is their availability in different dose strengths that pro-
vide an opportunity for individualized therapy. However, there is less experience with rhCG products in
Hungary, particularly due to the fact that until 2008, the use of rhCG products in IVF was not reimbursed
by the National Health Fund.
The equivalency between uhCG and rhCG preparations has been demonstrated by several well-de-
signed randomized clinical trials (RCTs). In 2005, a Cochrane review analyzed seven RCTs, of those four
compared rhCG and uhCG products. There was no statistically signiﬁcant difference between rhCG and
uhCG regarding the ongoing pregnancy/live birth rate [2]. Later on, these results were reinforced by fur-
ther RCTs [3–6]. The current knowledge on the comparable efﬁcacy of uhCG and rhCG relies, however,
exclusively on RCT data. While RCTs are suitable to compare different therapeutic approaches in a well-
controlled environment on a selected patient population, the results are not necessarily representative for
the real life, where a more heterogenous patient population is treated without the strict monitoring required
by study sponsors. Therefore, a noninterventional or observational approach to obtain data about rhCG or
uhCG therapy may add valuable information on the efﬁcacy of these products under routine IVF practice.
Our IVF centre in Szent J´ anos Hospital, Budapest, Hungary, treats about 1,000 suitable infertile
women with IVF per year. In 2008, we started to switch to the regular use of rhCG instead of uhCG, as
during that time the National Health Fund approvedthe reimbursement of rhCG. However, some colleagues
resisted this change and used uhCG further. In our retrospective analysis, we took the opportunity and
compared the IVF pregnancyoutcomes (pregnancy veriﬁed by laboratory tests and pregnancyfulﬁlled 24th
weeks of gestation) after administration of uhCG and rhCG products.
2. PATIENTS AND METHODS
In our retrospective analysis we collected data regarding the IVF procedures performed between February,
2008 and January, 2009 (start of rhCG reimbursement and retirement of colleagues preferring uhCG, resp.)
(Figure 1).
Infertile couples were assessed and the suitability of the woman, for IVF was established in
accordance with the Bourn Hall Guide to clinical and laboratory practice [7]. In eligible women multiple
ovarianfollicle developmentis achievedusingthe GnRHagonistlongprotocolorGnRHantagonistprotocol
combined with recombinant FSH.
In general,administration of GnRH agonist (0.1mg triptorelin s.c.,Decapeptyl 0.1mg/1mL, Ferring
GmbH Germany)is introduced in the luteal phase of the previous cycle. After 10–12 days of GnRH agonist
administration, once suppression is conﬁrmed, stimulation with 225IU of recombinant FSH (Gonal-F;
Merck-Serono, Geneva,Switzerland) or (Puregon Organon, Oss, Netherland)is started. The ﬁrst ultrasound
is performed on day 5 of stimulation. The dose of the gonadotropin can be increase or decreaseat this point
based on response.Ultrasound assessmentand serum E2 measurements are used to monitor follicle growth.
In cases of GnRH antagonist protocols, the ovarian stimulation is performed using a recombinant
FSH product (Gonal-F; Merck-Serono, Geneva, Switzerland). The initial gonadotropin dose is predeﬁned
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FIGURE 1: The selection of patients for our study.
at 225IU for all patients and is stable for 5 days; from this day onward, a 0.25mg/day GnRH antagonist is
coadministered (Cetrotide; Merck-Serono, Geneva, Switzerland or Orgalutran; Organon, Oss, Netherland).
The decision whether to use a GnRH agonist or a GnRH antagonist is based on patients’ preference
and on the experience during prior IVF cycles with the same patient [8].
As three leading follicles reach 17mm in diameter, rhCG or uhCG is administered to induce ﬁnal
follicular maturation.In general,thedoseofrhCG dependsonBMI, E2 levelsondayofhCG administration,
and the experience with previous IVF cycles. We give 6,500IU, 9,750IU, or 13,000IU to the patients in an
individualized manner, respectively. For uhCG, 10,000IU is administered consistently.
Our effective institutional guideline authorizes our IVF experts to decide whether rhCG or uhCG are
tobeadministeredprovidedthatthepatientisunder40yearsofage,isnotseverelyobese(BMI≥30kg/m2),
her basal FSH levels are under 12IU/L, and presented poor response to prior stimulation challenges (<3
oocytes, cancelled cycle, etc.). (If these criteria are not fulﬁlled, rhCG products are preferred to uHCG as
they allow individual dose titration.) Therefore, we limited our data collection to this population.
Transvaginal oocyte retrieval is scheduled 36 hours after the ﬁnal hCG injection. The maturity of
retrieved oocytes is assessed, then they are fertilised by conventional insemination or intracytoplasmatic
sperm injection (ICSI). The success of fertilization is assessed the following day. The embryos are cultured
for 3–5 days before implantation. Luteal support is administered in the form of 600mg micronized
progesterone vaginally in divided doses starting after oocyte retrieval (Utrogestan Lab Besius, France).
Our retrospectivedata collection wasapprovedby an institutional ethicalcommittee and fulﬁlls crite-
ria of Helsinki declaration.
From patients’ medical records, we obtained the following data: age, body mass index, number of
previous attempts; endometrial thickness, basal FSH value, use of GnRH agonists or antagonists, and use
doseofrhCGor uhCG.Asoutcomemeasures,pregnancyveriﬁedbylaboratorytestsandpregnancyfulﬁlled
24thweeksofgestationwereused.Incaseofseveralattemptsatthesamepatient(n =3)duringtheanalyzed
period the data of the last attempt were used in our analysis.
Clinical characteristics in rhCG and uhCG groups were compared by t-test (continuous variables)
or Chi-square test (dichotomic variables). The efﬁcacy of rhCG and uhCG was ﬁrst compared with Chi-
square test. The association between rhCG/uhCG use and outcome was adjusted to age, body mass index,
previous number of attempts, endometrium thickness, and use of GnRH agonist or antagonist using a logis-
tic regression model. P values under 0.05 were considered as statistically signiﬁcant.
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TABLE 1: Patients’ enrollment, clinical characteristics and outcomes. Abbreviations: rhCG: recombinant hu-
man chorionic gonadotropin; uHCG: urinary human chorionic gonadotropin; BMI: body mass index; GnRH:
gonadotrop-releasing hormone; IU: international unit; g.w: gestational week.
Clinical characteristics
rhCG uhCG
n = 391 96
Age (years) 32.5 ± 3.5 33.3 ± 3.7
BMI (kg/m2) 21.9 ± 2.6 22.5 ± 2.6
No. of previous attempts 1 ± 10 . 5 ± 1
Endometrium thickness (mm) 12 ± 2 11.5 ± 2
Therapeutic characteristics
GnRH agonists 159 46
GnRH antagonists 232 50
6500 IU dose 100 —
9750 IU dose 253 —
13000 IU dose 38 —
Outcome measures
Pregnancy outcomes Total:
Laboratory veriﬁed pregnancy (n =) 169 29∗ 198
Pregnancy over 24th g.w (n =) 110 20 130
Laboratory veriﬁed pregnancy (%) 43% 30% 40.6%
Pregnancy over 24th g.w (%) 28% 21% 26.7%
P = 0.021, Chi-square-test.
3. RESULTS
During the analysed12 months in 2008-2009,803 IVF procedureswere performed. Data of nonresponding,
obese, elder women and those with FSH above 12IU/mL were not included in the analysis (in total, n =
296), as this population is skewed to the use of rhCG due to institutional guidelines. Signs and symptoms
of suspected OHSS occurred in 15 on rhCG and in 3 patients on uhCG; the implantation was halted due to
intermittent disease in 2 further patients. Finally, pregnancy data of 391 and 96 women on rhCG and uhCG,
respectively, were compared (Table 1).
Theclinical characteristicsof bothgroupswere comparable.Laboratory-veriﬁedpregnancyoccurred
more frequently in rhCG patients thanin thoseonuhCG (oddsratio, OR [95% conﬁdenceinterval, CI]: 2.50
[1.40–4.35], P =0.002).Theassociationremainedsigniﬁcantafteritsadjustmentforclinicalcharacteristics
(Table 2). In addition to the beneﬁt associated with the use of rhCG, GnRH agonist use also increased the
occurrence of laboratory veriﬁed pregnancies, while in case of BMI, we observed a tendency (OR [95%
CI] 10.70 [10.12–20.58], P = 0.012, and OR [95% CI] 10.08 [0.99–10.17], P = 0.053, resp.). However,
the age correlated inversely and the number of previous attempts also tended inversely to the success (OR
[95% CI]: 0.93 [0.87–0.98], P = 0.014, and OR [95% CI] 0.87 [0.74–10.01], P = 0.080, resp.).
No difference regarding the rates of pregnancy over 24th gestational week was observed between
rhCG and uhCG groups by a Chi-square test. However, the association between the use of rhCG and
pregnancy was almost signiﬁcant (P = 0.056) in the logistic regression model when the contribution of
GnRH agonists (associated with higher rates), age, and number of previous attempts (associated with lower
rates) were also taken into account.
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TABLE2: The impact of rhCG/uHCG use and clinical characteristicson the occurrence of laboratory-veriﬁed
pregnancy and pregnancy over 24th week of gestation. Results of logistic regression analysis.
Odds ratio 95% conﬁdence interval P value
Laboratory-veriﬁedpregnancy
rhCG 2.50 1.40 4.35 0.002
Age 0.93 0.87 0.98 0.014
GnRH agonist use 10.70 10.12 20.58 0.012
BMI 10.08 0.99 10.17 0.053
Number of previous attempts 0.87 0.74 10.01 0.080
Endometrium thickness 10.04 0.95 10.13 0.442
Pregnancy over 24th g.w
rhCG 1.81 0.98 3.33 0.058
Age 0.90 0.84 0.96 0.002
GnRH agonist use 1.87 1.20 2.92 0.005
BMI 1.00 0.91 1.09 1.000
Number of previous attempts 0.83 0.69 1.01 0.067
Endometrium thickness 1.04 0.95 1.15 0.410
TABLE 3: Oocyte, MII, zygote, and embryo numbers with rhCG and uhCG products in assisted repro-
duction. Data are presented as median, interquartile range.
rhCG uhCG
Patient number 391 96
Oocyte number 7 (5–8) 6 (5–9)
MII number 5 (4–8) 6 (3.5–8)
Zygote number 5 (4–7) 5 (3–7)
Number of cleavaged embryos 5 (3–7) 5 (3–7)
Number of transferable embryos 4 (3–6) 4 (2–6)
No signiﬁcant difference in oocytenumbers, MII numbers, zygote numbers, cleavagedembryo num-
bers, and transferable embryo numbers was obtained between rhCG- and uhCG-treated groups (Table 3).
4. DISCUSSION
In the analyzed time period, uhCG and rhCG preparations were used simultaneously in our institute for IVF
procedures in women with low-risk for OHSS or resistance to ovulation induction. At this time personal
preferences to the use of uhCG and rhCG preparations in this patient population differed, and this provided
an opportunity for us to perform a direct comparison between these products. In our analysis, we did not
aim to create a homogenous population; instead, we wanted to collect data regarding “real-life” patients.
Therefore, the criteria for patients’ enrollment were not strict and were used just to identify that high-risk
population, where rhCG-preparations were already used in a routine manner.
The results of our observational study indicate that laboratory-veriﬁed pregnancy is positively
associated with the use of rhCG with an about 13% increase in its rate. In addition, a 7% (nonsigniﬁcant)
increase in rates of pregnancy fulﬁlling the 24th gestational week was also noted. As patients were
heterogenous in term of clinical characteristics, we adjusted these observations to these factors, and these
associations were maintained (and the positive effect of rhCG on ongoing pregnancy became also near
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signiﬁcant). While our retrospective analysis did not allow to explore the causes, one should speculate that
advantage in rhCG use compared to uhCG such as products’ availability in different dose strengths and no
batch-to-batch inconsistency may be translated to improved outcomes.
Some of the clinical and therapeutic factors that we adjusted for had also an impact on pregnancy
outcomes. Of these, patients’ age is well established [9] although it is important to emphasize that we did
not enrolled women with ≥40 years of age. The same applies for BMI; as we omitted obese subjects from
our analysis, the documented adverse effect of obesity on IVF success could not be demonstrated [10,
11]. Instead, a rather positive association between BMI and laboratory-veriﬁed pregnancies was detected,
indicating that higher, but still normal BMI (that is possibly associated with higher estrogen levels due
to aromatase activity in adipose tissues [12]) is positively associated with outcome. The almost signiﬁcant
inverse association of pregnancieswith the numberof unsuccessfulIVF cycles also supports current literary
data [13].
Another important and striking observation of our work is the signiﬁcant beneﬁt of GnRH agonists
compared to GnRH antagonists. This is in contrast to our previous observation [8] and also to the report
of Bodri et al. who conducted a systematic review and concluded that ongoing pregnancy rate is similar
with these drugs [14]. As the goal of our present analysis was to compare rhCG and uhCG preparations,
we cannot explore the mechanism of this ﬁnding. As GnRH agonist and antagonist treatment depended on
patient’s preference and/or history with previous attempts, the use of this drug was equally distributed in
rhCG and uhCG patients and was independent of patients’ clinical characteristics. This ﬁnding, therefore,
may indicate that (1) under real-life conditions, GnRH agonist and antagonist treatment is not equally
effective, or (2) personal preference to GnRH agonist or antagonist is linked to some undetected feature
(e.g., educational or socioeconomical status) that may contribute different results. Further targeted studies
are required to elucidate this issue.
During the recent decade, several RCT-s have been published on the efﬁcacy and suitability of
rhCG in IVF. RCT-s have, however, inherent limitations due to strict patient enrollment criteria. Therefore,
postmarketing studies are required to establish RCT results in real life. In our observational study, we de-
tected signiﬁcant advantage of rhCG over uhCG in terms of laboratory-veriﬁed pregnancy. Therefore, we
consider that this retrospective study adds important information to the existing and extensive knowledge
on the clinical efﬁcacy of rhCG preparations during an IVF procedure.
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